Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has confirmed ENS by physician diagnosis~* Patient has confirmed FGF23 elevations in the context of low serum phosphorous \< 4.1 mg/dL~* Patient able to tolerate KRN23 treatment~* Have a corrected serum calcium level \< 10.8mg/dL~* Have an eGFR \>60 ml/min~* Must be willing in the opinion of the investigator, to comply with study procedures and schedule~* Provide written informed consent by a parent after~Exclusion Criteria:~* Patient should not use CRYSVITA with Oral phosphate or active Vitamin D analogs.~* Patient and investigator should not initiate CRYSVITA if Phosphorus level is within or above normal.~* CRYSVITA is contraindicated in patients with severe renal impairment or end stage renal disease because these conditions are associated with abnormal mineral metabolism.~* The use or enrollment in studies using other investigational therapies including other monoclonal antibodies~* Subject and their Parent not willing or not able to give written informed consent~* In the Investigators opinion, the subject may not be able to meet all the requirements for study participation~* Subject has a history of hypersensitivity to KRN23 excipients that in the opinion of the investigator, places the subject at an increased risk of adverse effects~* Subject has a condition that in the opinion of the investigator could present a concern for subject safety or data interpretation.

- Gender: MALE
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crysvita (burosumab-twza) Treatment (Type: EXPERIMENTAL): The starting dose will be 0.3 mg/kg to be given every 2 weeks. If required dose may be titrated with increments of 0.1 mg/kg/dose every 4 weeks up to a maximum of dose of 2.0mg/kg (not to exceed 90mg per dose) until phosphorus level is WNL.~Patient will receive study drug via SC injection to the abdomen, upper arms, thighs, or buttocks; the injection site will be rotated with each injection. If the dose level exceeds 1.5 mL in volume, the dose should be administered at two injection sites.~Duration of treatment is 52 weeks. Subjects that complete treatment through week 52 may have the option to continue KRN23 treatment. If this is warranted based on preliminary efficacy, the current protocol will be amended to allow for an extension.

Based on this trial design, predict the completion outcome and termination type (if applicable).